© 2005 Oxford University Press
ARTICLE |
Paternity Following Treatment for Testicular Cancer
Affiliations of authors: Department of Oncology (MB, OD) and Centre for Clinical Research (TW-L), Haukeland University Hospital, and Section of Oncology, Institute of Medicine, University of Bergen (MB, OD), Bergen, Norway; St. Olav University Hospital and Norwegian University of Science and Technology, Trondheim, Norway (OK); University of Tromsø and University Hospital of Northern Norway, Tromsø, Norway (RMB); Norwegian Radium Hospital (SDF), Ullevål University Hospital (EAW), and University of Oslo Medical Faculty (EAW, SDF), Oslo, Norway
Correspondence to: Marianne Brydøy, MD, Department of Oncology and Medical Physics, Haukeland University Hospital, N-5021 Bergen, Norway (e-mail: marianne.brydoy{at}helse-bergen.no).
Background: Studies of fertility in men treated for testicular cancer have mainly addressed serum follicle-stimulating hormone levels and sperm parameters. We assessed post-treatment paternity among long-term survivors of testicular cancer. Methods: Men (n = 1814) who had been treated for unilateral testicular cancer in Norway during 1980 through 1994 were invited to participate in a national multi-center follow-up survey in 1998 through 2002. The participants were allocated to five groups according to the treatment received after orchiectomy, including treatment at relapse (surveillance, retroperitoneal lymph node dissection, radiotherapy, low-dose chemotherapy [i.e., 
850 mg cisplatin], and high-dose chemotherapy [i.e., >850 mg cisplatin]). Cox proportional hazards analysis was used to assess predictive factors for post-treatment paternity. Statistical tests were two-sided. Results: A total of 1433 men were assessable, of whom 827 were fathers at diagnosis. Post-treatment conception was attempted by 554 men, among whom the overall 15-year actuarial post-treatment paternity rate was 71% (95% confidence interval [CI] = 66% to 75%) without the use of cryopreserved semen. This rate ranged from 48% (95% CI = 30% to 69%) in the high-dose chemotherapy group to 92% (95% CI = 78% to 98%) in the surveillance group (P<.001). The median actuarial time from diagnosis to the birth of the first child after treatment was 6.6 years overall but varied according to treatment. Assisted reproductive technologies were used by 22% of the couples who attempted conception after treatment. Dry ejaculation, treatment group, pretreatment fatherhood, and marital status were statistically significant independent predictors for post-treatment fatherhood, with dry ejaculation as the most important negative factor. Conclusions: Although the overall paternity rate after treatment for testicular cancer was high, the ability to conceive and the time to conception reflected the intensity of treatment. These data may help inform patients about their future ability to father biological children.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Doctor ... Will I Still Be Able To Have Children?
- Scott Saxman
J Natl Cancer Inst 2005 97: 1557-1559.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Fossa, E. Gilbert, G. M. Dores, J. Chen, K. A. McGlynn, S. Schonfeld, H. Storm, P. Hall, E. Holowaty, A. Andersen, et al. Noncancer Causes of Death in Survivors of Testicular Cancer J Natl Cancer Inst, April 4, 2007; 99(7): 533 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Haugnes, N Aass, S. Fossa, O Dahl, O Klepp, E. Wist, J Svartberg, T Wilsgaard, and R. Bremnes Components of the metabolic syndrome in long-term survivors of testicular cancer Ann. Onc., February 1, 2007; 18(2): 241 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.E. Hoei-Hansen, E. Carlsen, N. Jorgensen, H. Leffers, N.E. Skakkebaek, and E. Rajpert-De Meyts Towards a non-invasive method for early detection of testicular neoplasia in semen samples by identification of fetal germ cell-specific markers Hum. Reprod., January 1, 2007; 22(1): 167 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de Wit and K. Fizazi Controversies in the Management of Clinical Stage I Testis Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Saxman Doctor ... Will I Still Be Able To Have Children? J Natl Cancer Inst, November 2, 2005; 97(21): 1557 - 1559. [Full Text] [PDF]
|
|